A small lump after a MOTS-c or peptide injection can happen from local irritation, minor bleeding, inflammation, or repeated use of the same injection area. Many mild bumps improve over days, but spreading redness, warmth, severe pain, pus, fever, rapid growth, or a lump that persists should be reviewed by a clinician 8 9 10.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What does a lump after a MOTS-c injection usually mean?
A lump after MOTS-c may be a local injection site reaction, not proof that the peptide is working or that something dangerous is happening. Mild bumps can happen with subcutaneous injections, but a clinician should review symptoms that worsen, spread, drain, or last longer than expected 8 9 10.
Subcutaneous injection means the product is placed into the fatty layer under the skin. That small space can react to fluid volume, needle irritation, local inflammation, minor bleeding, or repeated use of the same area 8.
| Feature | Often mild | More concerning |
|---|---|---|
| Size | Small bump that is stable or shrinking | Rapidly enlarging lump or a large, tense area |
| Pain | Mild soreness or tenderness | Severe pain or pain that is getting worse |
| Skin color | Small area of pinkness or a bruise | Spreading redness, streaking, blistering, or skin breakdown |
| Warmth | Mild warmth right after injection | Increasing warmth with swelling and pain |
| Drainage | None | Pus, cloudy fluid, blood that will not stop, or an open sore |
| Whole-body symptoms | None | Fever, chills, hives, facial swelling, dizziness, or breathing symptoms |
This article cannot confirm the cause of your lump. Skin infections, sterile nodules, bruises, granulomas, allergic-type reactions, and technique-related irritation can look similar early on 8 9 10 11.
What is MOTS-c, and how much human evidence exists?
MOTS-c stands for mitochondrial ORF of the 12S rRNA type-c. It is a mitochondrial-derived peptide, meaning it comes from genetic instructions linked to mitochondria, the cell structures that help make energy 6.
Researchers are interested in MOTS-c because it appears to be involved in metabolic stress signaling, AMPK pathways, and AICAR-related biology in lab and preclinical work 6. That does not mean injected MOTS-c is proven to improve human longevity, insulin sensitivity, body weight, or performance.
The human evidence is still narrow. Studies have measured circulating MOTS-c in settings such as endurance exercise, aerobic and resistance exercise in breast cancer survivors, heat stress during limb immobilization, metformin exposure, and cardiovascular or metabolic risk markers 1 2 3 4 5.
A ClinicalTrials.gov record lists a Phase 2 trial with 120 planned participants studying MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity, and it is listed as recruiting 7. Because that trial is recruiting, it should not be treated as proof of benefit.
| Evidence area | What has been studied | What it does not prove |
|---|---|---|
| Exercise | Acute endurance exercise and exercise programs have been studied with circulating mitochondrial-derived peptides, including MOTS-c 3 5. | It does not prove injected MOTS-c gives the same results as exercise. |
| Heat stress | Repeated heat stress has been studied for changes in MOTS-c and FGF21 during calf muscle immobilization 4. | It does not prove MOTS-c injections improve recovery or performance. |
| Metformin and cancer survivorship | Researchers have measured circulating MOTS-c in patients treated with metformin and in breast cancer survivor exercise research 1 3. | It does not prove MOTS-c treats cancer or replaces standard care. |
| Prediabetes and overweight/obesity | A Phase 2 trial is recruiting to study MOTS-c and insulin sensitivity 7. | It does not yet provide published outcome results. |
What can cause a hard lump after a peptide injection?
A hard lump after a subcutaneous peptide injection can come from several different processes. Common causes include irritation, inflammation, bruising, and repeated injections into the same area; less common but important causes include infection, abscess, allergic reaction, sterile nodule, lipohypertrophy, or granuloma 8 9 10 11 12.
Local inflammation or irritation
Needle entry, the injected fluid, preservatives, pH, concentration, or local tissue sensitivity can irritate the skin and fat layer. This may cause swelling, tenderness, itching, or erythema, which means redness of the skin 8.
Bruising or small bleeding under the skin
A small blood vessel can be nicked during an injection. That can create a bruise or firm tender spot under the skin, especially if the area is rubbed hard or if the person takes medicines that affect bleeding risk 8.
Repeated injections into the same area
Using the same spot again and again can irritate tissue and may contribute to firm areas. In people who inject medications regularly, repeated injections are linked with tissue changes such as lipohypertrophy, which is a thickened or rubbery area under the skin 8 12.
Possible sterile nodule, lipohypertrophy, or granuloma
A sterile nodule is a firm lump that is not caused by infection. A granuloma is a localized immune reaction. These can look like a persistent bump and should be reviewed if they do not improve or if the diagnosis is unclear 8 12.
Infection or abscess
Cellulitis is a skin infection that can cause spreading redness, warmth, swelling, and pain. An abscess is a pocket of infection that may feel very tender, soft, or fluctuant and may drain pus. These need clinician evaluation 9 10.
Allergic-type reactions
Itching, hives, flushing, swelling away from the injection site, throat tightness, wheezing, dizziness, or facial swelling can suggest an allergic-type reaction. Breathing symptoms or facial, lip, or tongue swelling should be treated as urgent 11.
How long should a peptide injection lump last?
A mild injection site lump often improves over days. Some firm areas can take longer to soften, especially if there was bruising, repeated local irritation, or a deeper tissue reaction 8.
Persistence matters. A lump that lasts beyond the expected period, keeps growing, becomes more painful, or has skin changes should be reviewed by a clinician rather than watched indefinitely 8 9 10.
| Timeline | What may be happening | Reasonable next step |
|---|---|---|
| Hours to a few days | Mild local swelling, irritation, or small bruise | Monitor if symptoms are mild and improving |
| Several days to 2 weeks | Bruising, firm irritation, or tissue reaction may be slowly improving | Contact the prescribing care team if it is not clearly getting better |
| More than 2 weeks or worsening anytime | Persistent nodule, granuloma, lipohypertrophy, infection, or another cause | Schedule clinician review |
| Any time with fever, pus, rapid growth, or severe pain | Possible infection, abscess, or serious reaction | Seek urgent clinical guidance |
What symptoms mean you should contact a clinician urgently?
Contact a clinician urgently if the lump is getting worse, spreading, draining, or paired with whole-body symptoms. With possible allergic reaction symptoms, such as breathing trouble or facial swelling, seek emergency care 9 10 11.
| Symptom | Why it matters |
|---|---|
| Spreading redness, warmth, or worsening pain | Can be a sign of cellulitis or deeper inflammation 9 |
| Drainage, pus, blistering, or skin breakdown | Can suggest infection, abscess, or tissue injury 10 |
| Fever, chills, or feeling ill | Can mean the reaction is not only local 9 10 |
| Rapidly enlarging lump or severe tenderness | Needs review for abscess, bleeding, or another complication 8 10 |
| Hives, facial swelling, throat tightness, wheezing, or breathing symptoms | Can suggest an allergic reaction and may be urgent 11 |
What should you do if the lump appeared after MOTS-c from an online source?
If the lump appeared after MOTS-c from an online source, contact the prescribing clinician or pharmacy that supplied it. If there was no prescribing clinician, the safety uncertainty is higher because sterility, concentration, storage, and identity may be unclear.
Injectable products carry special risks because they bypass the skin barrier. Source quality, sterile handling, single-use supplies, and accurate concentration all matter. Buying investigational peptides without medical oversight can make it harder to know what was injected or how to respond to a reaction.
Do not change the dose, concentration, injection route, or injection schedule on your own. If the product was compounded by a pharmacy outside Chia, the pharmacy and prescribing clinician are the right first contacts for product-specific questions.
Does Chia offer MOTS-c treatment?
Chia does not currently offer MOTS-c. We publish MOTS-c education because patients ask thoughtful questions about peptide safety, but MOTS-c is not listed in our current treatment catalog.
At Chia, our approach is to separate human evidence from animal and cell findings, distinguish approved indications from investigational use, and keep access tied to licensed-provider review. For broader reading, see our guides to MOTS-c evidence and access, MOTS-c injection questions, and MOTS-c peptide dosing limits.
For patients comparing prescribed peptide options, our current catalog includes treatments such as Sermorelin, NAD+, glutathione, and GHK-Cu, each reviewed by a licensed US provider when clinically appropriate. These are different compounds from MOTS-c and should not be treated as substitutes.
If your main question is whether a reaction is normal, our general peptide safety guide and our article on sermorelin injection site reactions may help you frame questions for your own clinician. You can also read our broader overview of peptide side effects.
How can injection site reactions be reduced in general?
In general, site rotation and sterile technique help reduce injection site problems. But technique should be taught by the prescribing care team, because injection route, supplies, and instructions depend on the specific medication and patient 8 12.
- Rotate injection areas as directed by the prescribing clinician instead of repeatedly using the same exact spot.
- Use sterile, single-use needles and supplies when an injectable medication is prescribed.
- Do not reuse needles or share injection supplies.
- Do not massage, heat, or press on a lump unless your clinician says it is appropriate for your situation.
- Do not change dose, concentration, route, or schedule without the prescribing clinician.
If you are using a prescribed treatment through Chia, your care team can answer technique questions through the patient portal. If you are using MOTS-c from another clinic or pharmacy, contact that prescriber or pharmacy because Chia does not supply MOTS-c.
A small, mildly tender bump can happen after a subcutaneous peptide injection. It may come from local irritation, swelling, or minor bruising. A bump that spreads, drains, becomes very painful, grows quickly, or comes with fever or allergic symptoms should be reviewed by a clinician.
A hard lump can come from inflammation, bruising, repeated injections in the same area, a sterile nodule, lipohypertrophy, granuloma, or infection. The cause cannot be confirmed online, so persistent or worsening lumps should be checked by a licensed clinician.
Many mild injection site lumps improve over days. Some firm areas can take longer, especially if there is bruising or repeated irritation. If the lump is not improving, lasts more than about two weeks, or has red flags, contact a clinician.
Mild swelling may improve within a few days, while a firmer bruise or tissue reaction can take longer. A lump that keeps growing, becomes more painful, drains, or persists should not be ignored.
Any injection can introduce infection risk if sterility is poor or skin bacteria enter the tissue. Signs can include spreading redness, warmth, worsening pain, pus, fever, or feeling ill. These symptoms need medical review.
Do not make medication changes on your own. Contact the clinician who prescribed or supplied the MOTS-c, especially if the lump is painful, spreading, persistent, or paired with whole-body symptoms.
Ask your prescribing clinician first. Massage may not be appropriate if there is bruising, infection, severe tenderness, or skin breakdown.
No. Chia does not currently offer MOTS-c. We provide education about MOTS-c and peptide safety, but patients using MOTS-c should contact the clinician or pharmacy that supplied it.
References
- 1.Cuyàs E, Verdura S, Martin-Castillo B, et al. Circulating levels of MOTS-c in patients with breast cancer treated with metformin. Aging. 2022.
- 2.Ikonomidis I, Katogiannis K, Kyriakou E, et al. β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. Journal of Thrombosis and Thrombolysis. 2020.
- 3.Dieli-Conwright CM, Sami N, Norris MK, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports. 2021.
- 4.Elhusseiny R, Ihsan M, Labidi M, et al. Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Medicine & Science in Sports & Exercise. 2025.
- 5.von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology. 2021.
- 6.Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023.
- 7.ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. NCT07505745. 2026.
- 8.DermNet NZ. Injection site reactions. Accessed 2026.
- 9.MedlinePlus Medical Encyclopedia. Cellulitis. Accessed 2026.
- 10.MedlinePlus Medical Encyclopedia. Skin abscess. Accessed 2026.
- 11.MedlinePlus Medical Encyclopedia. Anaphylaxis. Accessed 2026.
- 12.Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. American Journal of Clinical Dermatology. 2003.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
